Menopause Completed Phase 3 Trials for Risedronic acid (DB00884)

Also known as: Menopausal

IndicationStatusPhase
DBCOND0025857 (Menopause)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00859703Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast CancerTreatment